Insulin and the future of diabetes treatment
15
What in your opinion are some of the most relevant advances in insulin technology in the last decade?
160
What may be the role of dual GIP and GLP-1 agonists in T2D?
269
What do you think the future will hold in terms of artificial intelligence?
Gender differences in cardiovascular risk, treatment, and outcomes: a post-hoc analysis from the REWIND trial
15
In brief, what were the main findings of the REWIND trial?
63
What are the salient conclusions of this new post-hoc analysis?
177
Are there any clinical implications for daily practice from this new subanalysis?
Glucose sensors on the rise: new technologies?
15
What limitations are there in current glucose-sensing technology?
124
Are non-invasive methods for glucose-sensing a realistic goal?
190
Can new technologies be expected to expand the demand for use of glucose sensing devices?
Tirzepatide vs insulin degludec on liver fat content and abdominal adipose tissue in patients with T2D (SURPASS-3 MRI)
15
What were the main findings of the SURPASS-3 trial, and what has been investigated in the substudy SURPASS-3 MRI?
150
What are the findings of the SURPASS-3 MRI substudy?
294
Do the findings of SURPASS-3 MRI have the potential to change clinical practice?
Michael Berger Debate: Who suffers more: Are women with diabetes at higher cardiovascular risk?
15
Michael Berger Debate: Who suffers more: Are women with diabetes at higher cardiovascular risk?
226
What are some of the reasons why women with diabetes are at greater cardiovascular risk?
413
How can clinicians treat women with diabetes more effectively?
Personalising the treatment for patients with type 2 diabetes: the mean is meaningless
15
What are some of the hurdles to overcome in achieving personalized targets for renal function?
136
What practical guidance do prescribers need in order to personalise treatment of renal comorbidities?
217
Why do some patients respond to treatment differently than others?
Management of type 1 diabetes: ADA-EASD Consensus Report 2021
15
Management of type 1 diabetes: ADA-EASD Consensus Report 2021
119
Is the use of multiple hormones and advantage in treatment of type 1 diabetes and what additional challenges does this pose?
260
What does the future hold in terms of insulins with a more physiological profile?
KDIGO guidelines for treating type 2 diabetes with CKD
15
How do current KIDGO guidelines/recommendations differ from those in the past?
93
What gaps in the EASD/ADA guidelines do the KIDGO recommendations attempt to fill?
228
How important is comprehensive care in patients with diabetes and CKD?
